Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Opsens Temettü

Temettü kriter kontrolleri 0/6

Opsens şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	1.7%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-CA$0.11
Temettü verim tahmini	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Opsens Inc. (TSE:OPS) Just Reported And Analysts Have Been Lifting Their Price Targets

Nov 23

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: OPS şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: OPS şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Opsens Piyasaya Karşı Temettü Getirisi

OPS temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (OPS)	n/a
Pazarın Alt %25'i (CA)	1.7%
Pazarın En İyi %25'i (CA)	5.8%
Sektör Ortalaması (Medical Equipment)	1.7%
Analist tahmini (OPS) (3 yıla kadar)	n/a

Önemli Temettü: OPS şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, OPS şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: OPS şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: OPS herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Opsens Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS).

Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS).

Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for CAD 345 million.

New minor risk - Share price stability

Forecast to breakeven in 2025

Opsens Inc. to Report Q3, 2023 Results on Jul 13, 2023

Potential Upside For Opsens Inc. (TSE:OPS) Not Without Risk

New major risk - Financial position

OpSens Inc. Announces Inclusion of Savvywire™ in COMPLETE TAVR Study

Independent Director recently sold CA$79k worth of stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Consensus forecasts updated

No longer forecast to breakeven

First quarter 2023 earnings: Revenues exceed analyst expectations

Opsens Inc. to Report Q1, 2023 Results on Jan 12, 2023

Opsens Inc. has completed a Follow-on Equity Offering in the amount of CAD 10 million.

Price target decreased to CA$3.73

Consensus EPS estimates fall by 27%

Consensus EPS estimates fall by 21%

Full year 2022 earnings: EPS misses analyst expectations

Opsens Inc. to Report Q4, 2022 Results on Nov 22, 2022

Opsens Inc. to Report Q4, 2022 Results on Nov 22, 2022

Insufficient new directors

Opsens Inc., Annual General Meeting, Jan 24, 2023

Opsens Inc. Announces Departure of Robin Villeneuve as Corporate Secretary, Effective December 9, 2022

Opsens Inc. Announces First Savvywire Clinical Cases in Europe and Launch of Safe-Tavi Study

Opsens Announces First Savvywire Procedure in the United States by Dr. Philippe Genereux of Morristown Medical Center

OpSens Inc. Announces FDA Clearance for the SavvyWire for Use in Transcatheter Aortic Valve Replacement (TAVR) Procedures

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Forecast breakeven date pushed back to 2024

Opsens Inc. to Report Q3, 2022 Results on Jul 14, 2022

CFO & Corporate Secretary exercised options to buy CA$115k worth of stock.

CFO & Corporate Secretary exercised options and sold CA$75k worth of stock

Opsens Inc. Announces New Data Supporting the Safety and Efficacy of its SavvyWire Recently Approved by Health Canada for Transcatheter Aortic Valve Replacement Procedures

Insufficient new directors

Opsens Inc. Announces Health Canada Approval for Its New TAVR Guidewire

Consensus EPS estimates fall by 69%

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Opsens Inc. to Report Q2, 2022 Results on Apr 13, 2022

Insufficient new directors

Insufficient new directors

OpSens Inc Appoints Brad Davis as Chief Commercial Officer

Independent Director exercised options to buy CA$245k worth of stock.

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Opsens Inc. Announces 510(K) Submission to U.S. FDA for New Guidewire for the Tavr Procedure

Forecast breakeven date pushed back to 2023

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to CA$4.28

Opsens Inc. Successfully Completes 20-Patient in Human Clinical Study for TAVR Procedure

Independent Director recently sold CA$139k worth of stock

Independent Director exercised options to buy CA$368k worth of stock.

President exercised options and sold CA$230k worth of stock

Director recently bought CA$310k worth of stock

Director recently bought CA$310k worth of stock

Price target increased to CA$3.79

OPSENS Receives Approval from Health Canada to Initiate First In-Man Clinical Study for its New Guidewire for the TAVR Procedure

Insufficient new directors

Independent Director recently bought CA$150k worth of stock

Independent Director recently bought CA$150k worth of stock

Consensus forecasts updated

Third quarter 2021 earnings released

Opsens (TSE:OPS) Has Debt But No Earnings; Should You Worry?

Price target increased to CA$3.00

Second quarter 2021 earnings released: EPS CA$0.001 (vs CA$0.015 loss in 2Q 2020)

Price target raised to CA$2.56

Opsens Inc. has completed a Follow-on Equity Offering in the amount of CAD 25 million.

Is Opsens (TSE:OPS) Weighed On By Its Debt Load?

Opsens Inc. Obtains CE Marking for the OptoWire III

Revenue and earnings beat expectations

Price target raised to CA$2.13

Revenue and earnings beat expectations

First quarter 2021 earnings released: EPS CA$0.01